Transgenomic Prepares for Planned Relisting On NASDAQ
Jun 21, 2017
www.otcmarkets.com/stock/TBIOD/news/...ASDAQ?id=162663&b=y
Transgenomic Inc. (OTCQB:TBIOD) today announced that it is advancing its previously announced plans for relisting on the NASDAQ Capital Market.
After receiving shareholder approval, the company implemented a reverse split of its shares on June 13, 2017, in order to meet NASDAQ relisting requirements of a closing share price at or above $4.00 for five consecutive trading days.
Other relisting requirements involve shareholder equity.
Upon the completion of the merger between Transgenomic and Precipio Diagnostics, which is expected to occur in the next few days, the companies believe that the combined entity will satisfy the NASDAQ relisting requirements.
usw. ....